The dean of the Texas A&M Health Science Center School of Public Health Jay Maddock, Ph.D., was selected to become a member of the Texas Department of State Health Services (DSHS) Public Health Funding and Policy Committee, which was established by Senate Bill 969 in the 82nd Texas Legislative Session.
Kirk Cole, the Interim DSHS Commissioner, stated in a press release: “We are privileged to have the benefit of Dr. Maddock’s expertise and experience in advising the department on public health funding and policy issues in Texas.”
The committee will advise local public health entities, which include local health departments, health units and public health districts, on several issues concerning funding and bridging the communication gap between the DSHS and the public health agencies. They will also offer advice on other general public health policy issues that involve the state.
Maddock has an undergraduate degree in psychology and sociology from Syracuse University and a master’s degree and doctorate in experimental psychology from the University of Rhode Island. He was also given the Award of Excellence, granted by the American Public Health Association’s Council on Affiliates, and was nominated as a charter member of the National Institutes of Health study section on Community-Level Health Promotion. He was also nominated by the Bank of Hawaii as Community Leader of the Year, and served as chair of the Hawaii State Board of Health, co-authoring the state’s Physical Activity and Nutrition Plan.
He was recently nominated as the new dean of the Texas A&M University in February. Before his current position, he served for eight years as the director of the Public Health Program at the University of Hawaii.
Life Sciences firms have always understood the importance of reliable data in the lab, but what about collecting and understanding customer data for successful marketing efforts? The emergence of Big Data has allowed these companies to more fully engage with their customers, employees, investors, and suppliers, yet many firms still have not established value-added connections with these different customer groups. But connection to the customer could be the most valuable asset of a Life Sciences firm. In a recent Forbes.com article, marketing expert Niraj Dawar points out that pharmaceutical companies with an emphasis on subscriber and doctor relationships are in the “driver’s seat” of the industry, acquiring the firms that solely rely on technological strength and patents.